


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-45. (canceled)

46. (Canceled)

47. (Currently amended) A compound ~~according to claim 46~~ having the formula



or a N-oxide form, a pharmaceutically acceptable addition salt and stereo-chemically isomeric form thereof, wherein[[;]]

n represents an integer being 0, 1, or 2;

m represents an integer being 1;

R¹ represents Ar¹, C₁₋₄alkyl, or C₁₋₄alkyl substituted with morpholinyl;

R² and R³ taken together with the carbon atom to which they are attached form a

C₃₋₈cycloalkyl or Het¹ wherein said C₃₋₈cycloalkyl or Het¹ each independently may optionally be substituted with C₁₋₄alkyloxycarbonyl;

R⁴ represents halo or ~~R⁴ represents~~ C₁₋₄alkyloxy;

R⁵ represents C₁₋₄alkyloxycarbonyl, -O-(mono- or di(C₁₋₄alkyl)aminosulfonyl), C₁₋₄alkyl substituted with one or where possible more substituent being selected from Het³ or NR⁶R⁷,

C₁₋₄alkyloxy substituted with one or where possible more substituents being selected from amino, Het⁴ or NR⁸R⁹;

R⁶ and R⁷ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, Het⁵ or C₁₋₄alkyl substituted with one or where possible more substituents being selected from hydroxy or Het⁵;

R⁸ and R⁹ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, Het⁷ or mono- or di(C₁₋₄alkyl)aminosulfonyl;

Het¹ represents piperidinyl;

Het³ represents a heterocycle selected from morpholinyl, pyrrolidinyl, piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, C₁₋₄alkyl, aminosulfonyl, amino, mono- or di(C₁₋₄alkyl)aminosulfonyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁵ represents pyridinyl optionally substituted with mono- or di(C₁₋₄alkyl)aminosulfonyl;

Het⁷ represents piperidinyl optionally substituted with C₁₋₄alkylphenyl, C₁₋₄alkyloxycarbonyl, or mono- or di(C₁₋₄alkyl)aminosulfonyl;

Ar¹ represents an aryl substituent selected from phenyl or naphthalenyl;

48. (Currently amended) A compound according to claim [[46]] 47 wherein;

R¹ represents C₁₋₄alkyl;

R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl or piperidinyl wherein said C₃₋₈cycloalkyl or Het¹ each independently may optionally be substituted with C₁₋₄alkyloxycarbonyl;

R⁴ represents halo or C₁₋₄alkyloxy;

R⁵ represents C₁₋₄alkyloxycarbonyl, -O-(mono- or di(C₁₋₄alkyl)aminosulfonyl),

C₁₋₄alkyl substituted with one or where possible more substituent being selected from Het³ or NR⁶R⁷,

C₁₋₄alkyloxy substituted with one or where possible more substituents being selected from amino, Het⁴ or NR⁸R⁹;

R⁶ and R⁷ are each independently selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, -Het⁵ or C₁₋₄alkyl substituted with one or where possible more substituents being selected from hydroxy, or Het⁵;

R⁸ and R⁹ are each independently selected from hydrogen, C₁₋₄alkyl, -Het⁷ or mono- or di(C₁₋₄alkyl)aminosulfonyl;

Het³ represents a heterocycle selected from piperidinyl, or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from hydroxy, aminosulfonyl, amino, mono- or di(C₁₋₄alkyl)aminosulfonyl, hydroxyC₁₋₄alkyloxyC₁₋₄alkyl or C₁₋₄alkyloxy;

Het⁴ represents a heterocycle selected from morpholinyl, piperidinyl or piperazinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from C₁₋₄alkyl, C₁₋₄alkyloxycarbonyl or mono- or di(C₁₋₄alkyl)aminosulfonyl;

Het⁵ represents a heterocycle selected from pyridinyl or piperidinyl wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible two or three substituents each independently selected from aminosulfonyl, or mono- or di(C₁₋₄alkyl)aminosulfonyl;

Het⁷ represents piperidinyl.

49. (Currently amended) A compound as claimed in claim [[46]] 47, wherein R² and R³ taken together with the carbon atom to which they are attached form a C₃₋₈cycloalkyl.

50. (Currently amended) A compound as claimed in claim [[49]] 47, wherein R² and R³ taken together with the carbon atom to which they are attached are cyclopentyl.

51. (Canceled)

52. (Canceled)


53. (Canceled)

54. (Currently amended) A compound as claimed in claim [[46]] 47, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl substituent, or Het⁴ consists of piperazinyl substituted with one mono- or di(C₁₋₄alkyl)aminosulfonyl substituent.


55. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in claim [[46]] 47.

56. (Currently amended) A process of preparing a compound as described in claim [[46]] 47, comprising

i) reacting a primary amine of formula (V) with an aldehyde of formula (VI) wherein Q is




in a condensation reaction using ethanol as a suitable solvent;



e) EtOH

ii) followed by a nitrosative cyclisation of the thus obtained Schiffs bases of formula (II) with NaNO_2 in acetic acid, and refluxing the nitroso intermediates of formula (III) in a suitable solvent such as acetic anhydride or ethanol further comprising dithiothreitol (DTT);



57. (Canceled)

58. (Currently amended) A compound as claimed claim [[57]] 49, wherein R^2 and R^3 taken together with the carbon atom to which they are attached form cyclopentyl.

59. (Currently amended) A compound according to claim [[46]] 47, provided that when R^5 represents NR^6R^7 , either R^6 or R^7 represents C_{1-4} alkylsulfonyl or C_{1-4} alkylcarbonyl.

60. (Previously presented) A compound according to claim 59, provided that when R^5 represents NR^6R^7 , either R^6 or R^7 represents methylsulfonyl or methylcarbonyl.

61. (Previously presented) A compound according to claim 60, provided that when R^5 represents NR^6R^7 , either R^6 or R^7 represents methylsulfonyl.

62. (Previously presented) A compound according to claim 60, provided that when R^5 represents NR^6R^7 , either R^6 or R^7 represents methylcarbonyl.

63. (Currently amended) A compound as claimed in claim ~~[[46]]~~ 47, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with one C₁₋₄alkyl substituent, or Het⁴ consists of piperazinyl substituted with one mono- or di(C₁₋₄alkyl)aminosulfonyl substituent.
64. (Previously presented) A compound as claimed in claim 63, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R⁵ substituent, or Het⁴ consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R⁵ substituent.
65. (Previously presented) A compound as claimed in claim 47, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R⁵ substituent, or Het⁴ consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R⁵ substituent.
66. (Previously presented) A compound as claimed in claim 48, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R⁵ substituent, or Het⁴ consists of piperazinyl substituted with dimethylaminosulfonyl in the para position relative to the carbon atom bearing the R⁵ substituent.
67. (Previously presented) A compound as claimed in claim 50, provided that when R⁵ represents a C₁₋₄alkyloxy substituted Het⁴, said Het⁴ being selected from the group consisting of

morpholinyl, piperidinyl, piperazinyl and piperazinyl substituted with methyl in the para position relative to the carbon atom bearing the R⁵ substituent, or Het⁴ consists of piperazinyl substituted with dimethylaminosulfonyl, in the para position relative to the carbon atom bearing the R⁵ substituent.